key: cord-0922308-g6vuczg7
authors: Taxonera, Carlos; Sagastagoitia, Iñigo; Alba, Cristina
title: Letter: immunotherapy for IBD patients in a SARS‐CoV‐2 endemic area—authors' reply
date: 2020-08-14
journal: Aliment Pharmacol Ther
DOI: 10.1111/apt.15955
sha: 1f58f1846b87b15eb4faba73b45e65620b8ba886
doc_id: 922308
cord_uid: g6vuczg7

LINKED CONTENT This article is linked to Taxonera et al and Szokodi papers. To view these articles, visit https://doi.org/10.1111/apt.15804 and https://doi.org/10.1111/apt.15897

This approach was adopted in the belief that immunosuppressants may be beneficial to control the cytokine storm in response to viral infection, which bears some resemblance to the process in IBD flares. 4 This strategy to contain the hyper-inflammatory state appeared successful; markers of systemic inflammation (including IL-6, CRP, ferritin and D-dimer levels) dropped progressively, and the patient was discharged without subsequent complications. In case of worsening, this patient would have been a candidate for treatment with tocilizumab, but the increase in cases of gastrointestinal perforation and abscesses observed in a clinical trial with an experimental anti-IL-6 agent for Crohn's disease call into question the benefit of tocilizumab, which also targets IL-6, in this specific case. 5 A recent review assessing the interaction between viral immunopathology and immunosuppressive and biologic drugs concluded that immunosuppressive therapy seems neither to have a major impact on infection with SARS CoV-1, MERS-CoV and SARS-CoV-2, nor to lead to a severe disease course in many cases. 6 Furthermore, evidence that TNF antagonist monotherapy was not associated with, and may even have a protective effect against, severe COVID-19 7 reinforces the need for trials evaluating these drugs for COVID-19. 8 In fact, a phase 2 trial of infliximab in COVID-19 has recently been registered. 9 Therefore, we agree that, since discontinuation of therapy is associated with an increased risk of IBD flare or worsening, we should recommend all our patients (without COVID-19) to continue the various immunosuppressants or biologic agents prescribed for their IBD.

The authors' declarations of personal and financial interests are unchanged from those in the original article. 2 

COVID-19: consider cytokine storm syndromes and immunosuppression

Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn's Disease (ANDANTE I and II)

Peyrin-Biroulet L Safety of drugs during previous and current coronavirus pandemics: lessons for IBD

Corticosteroids but not TNF antagonists, are associated with adverse COVID-19 outcomes in patients with inflammatory bowel diseases: results from an international registry

Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed